David Miklos is a Hematology physician affiliated with Stanford University. OpenAlex indexes 720 publications with 32,871 citations (h-index 62); ClinicalTrials.gov lists 3 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Hematology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
300 Pasteur Dr
Stanford, CA 943052200
Telephone
650-723-4000Provider last certified this registry record 15 Apr 2024.
Clinical trials
- 18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma
Sponsor: Stanford University
- Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
Sponsor: Stanford University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Adaptive Biotechnologies CorporationProgram year202510 payments
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
- Kite Pharma, Inc.Program year202512 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
38.5%Short-acting sulfonamides35%Sulfamethoxazole-Trimethoprim100%Part D≥42 patientsAzole Antifungal3.5%Posaconazole100%Part D<11 patientsDermatology
29.1%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor29.1%Acyclovir100%Part D≥37 patientsMetabolism & gastrointestinal
9.4%Serotonin-3 Receptor Antagonist4.1%Ondansetron Hcl100%Part D≥20 patientsCorticosteroid3.1%Prednisone100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2005–2025 per NIH RePORTER. The latest:
- Bone Marrow Grafting and Cellular Therapy for Leukemia and Lymphoma
Stanford University
FY2025$2,936,016P01CA049605 - Donor Derived CD19/CD22 CAR T Cells as Concurrent Therapy Against Relapse in Adults with B-ALL
Stanford University
FY2025$465,085P01CA049605
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy
New England Journal of Medicine
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Renumathy Dhanasekaran, MD, PhD
Stanford University
Euan Ashley, MD
Stanford University
Sarah Donaldson, MD
Stanford University
Peter Fitzgerald, MD
Stanford University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”